IDYAIdeaya Biosciences Inc

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs PR Newswire SOUTH SAN FRANCISCO, Calif., July 17, 2026 SOUTH SAN FRANCISCO, Calif., July 17, 2026...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., June 26, 2026 SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ --IDEAYA...

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a...

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SOUTH SAN FRANCISCO, Calif., June 10, 2026...

U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak earnings. Other stocks also down in pre-market.read more...

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif., June 8, 2026 SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA...

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif., June 8, 2026 SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences...

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer PR Newswire SOUTH SAN FRANCISCO, Calif., June 3, 2026 IDEAYA entered into a...

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO IDEAYA Biosciences and Servier Provide Complete Data from Phase...